Chili777 said:
lessthanhalf said:
Appreciate you sharing that. I have to say I lean toward doubt when the research is extremely niche and comes entirely from a single investigator or team — something that frequently seems tied to Russia or Eastern Europe, where during the Cold War the scientific enterprise developed apart from the West. My guess is this is a lingering consequence of that split: Russian studies largely stand alone, a few of these peptides are actually used in clinical settings over there, yet Western trials or reproductions are generally absent. I have talked this over with chatgpt.
Unless someone invests serious time checking each reference closely, the bulk — possibly all — of the epitalon research cited consists of cell-based work rather than human clinical trials. So if the benchmark is safe and effective in humans, calling the evidence strong seems like a stretch. If the discussion is only about reproducing the basic science, then I will not push back. Still, drawing those lines clearly matters, since real people are using these peptides. I realize the same researchers in Russia have run clinical trials, but what you really want is independent clinical trial replication. The incentive for that is probably weak: if these peptides occur naturally or were created in Russia, patenting them is likely impossible, which means no route for pharmaceutical companies to recoup the huge cost of clinical trials — so it probably will not happen.
You were quicker than me on that. Western research probably won't materialize, since western BP firms stand to gain nothing financially from it. I had just been reviewing what patents exist around the Khavinson bioregulators:
Patenting of Khavinson Bioregulators
Patent Landscape Summary
Vladimir Khavinson played a central role in creating peptide bioregulators, which find use in gerontology and medicine. His efforts have resulted in many patent filings covering these bioregulators.
Main Details
Patent Count: 196 patents are held by Khavinson, spanning Russian and international jurisdictions.
Peptide Varieties: More than 20 complexes of physiologically active peptides have been extracted by him, and 15 additional ones were synthesized from amino acids. Patents in multiple countries, among them the US, Canada, and Europe, protect these peptides.
Medicinal Application: 6 medicinal peptide preparations that Khavinson developed have received approval for medical use in Russia and other CIS countries.
The conclusion is that no rigorous research will be carried out either to confirm or refute his entire body of work.